Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022
Issued Date
2023-01-01
Resource Type
eISSN
27324303
Scopus ID
2-s2.0-85180798978
Journal Title
Immunotherapy Advances
Volume
3
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Immunotherapy Advances Vol.3 No.1 (2023)
Suggested Citation
Barnes M.V.C., Mandla A., Smith E., Maskuniitty M., Openshaw P.J.M., Abo Y.N., Ascough S., Ashwin H., Avirutnan P., Catchpole A.P., Chi P.C., Chiu C., Darton T.C., Driciru E., Dula D., Ferreira D.M., Fraser A., Garrett P., Gbesemete D., Gordon S., Heymann D.L., Houlder E., Jamrozik E., Kapulu M., Kessy E., Overgaard Kildemoes A.M., Koopman J.P., McShane H., Navanukroh O., Osier F.H., Osowicki J., Pham V., Pollard A.J., Ratta-Apha W., Silk S.E., Sridhar S., Swanson K.A., Talaat K.R., Thwaites R.S., Welch O. Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022. Immunotherapy Advances Vol.3 No.1 (2023). doi:10.1093/immadv/ltad024 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/96341
Title
Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022
Author(s)
Barnes M.V.C.
Mandla A.
Smith E.
Maskuniitty M.
Openshaw P.J.M.
Abo Y.N.
Ascough S.
Ashwin H.
Avirutnan P.
Catchpole A.P.
Chi P.C.
Chiu C.
Darton T.C.
Driciru E.
Dula D.
Ferreira D.M.
Fraser A.
Garrett P.
Gbesemete D.
Gordon S.
Heymann D.L.
Houlder E.
Jamrozik E.
Kapulu M.
Kessy E.
Overgaard Kildemoes A.M.
Koopman J.P.
McShane H.
Navanukroh O.
Osier F.H.
Osowicki J.
Pham V.
Pollard A.J.
Ratta-Apha W.
Silk S.E.
Sridhar S.
Swanson K.A.
Talaat K.R.
Thwaites R.S.
Welch O.
Mandla A.
Smith E.
Maskuniitty M.
Openshaw P.J.M.
Abo Y.N.
Ascough S.
Ashwin H.
Avirutnan P.
Catchpole A.P.
Chi P.C.
Chiu C.
Darton T.C.
Driciru E.
Dula D.
Ferreira D.M.
Fraser A.
Garrett P.
Gbesemete D.
Gordon S.
Heymann D.L.
Houlder E.
Jamrozik E.
Kapulu M.
Kessy E.
Overgaard Kildemoes A.M.
Koopman J.P.
McShane H.
Navanukroh O.
Osier F.H.
Osowicki J.
Pham V.
Pollard A.J.
Ratta-Apha W.
Silk S.E.
Sridhar S.
Swanson K.A.
Talaat K.R.
Thwaites R.S.
Welch O.
Author's Affiliation
Oxford University Clinical Research Unit
Malawi-Liverpool-Wellcome Trust Clinical Research Programme
Ifakara Health Institute
London School of Hygiene & Tropical Medicine
University of Oxford
University of Melbourne
Royal Children's Hospital, Melbourne
University of Southampton
Liverpool School of Tropical Medicine
University of York
Leids Universitair Medisch Centrum
Imperial College London
Mahidol University
National Heart and Lung Institute
Pfizer Inc.
Johns Hopkins University
The University of Sheffield
KEMRI Wellcome Research Programme
Sanofi Pasteur and Inno4Vac
1Day Sooner
hVIVO
Malawi-Liverpool-Wellcome Trust Clinical Research Programme
Ifakara Health Institute
London School of Hygiene & Tropical Medicine
University of Oxford
University of Melbourne
Royal Children's Hospital, Melbourne
University of Southampton
Liverpool School of Tropical Medicine
University of York
Leids Universitair Medisch Centrum
Imperial College London
Mahidol University
National Heart and Lung Institute
Pfizer Inc.
Johns Hopkins University
The University of Sheffield
KEMRI Wellcome Research Programme
Sanofi Pasteur and Inno4Vac
1Day Sooner
hVIVO
Corresponding Author(s)
Other Contributor(s)
Abstract
HIC-Vac is an international network of researchers dedicated to developing human infection challenge studies to accelerate vaccine development against pathogens of high global impact. The HIC-Vac Annual Meeting (3rd and 4th November 2022) brought together stakeholders including researchers, ethicists, volunteers, policymakers, industry partners, and funders with a strong representation from low- and middle-income countries. The network enables sharing of research findings, especially in endemic regions. Discussions included pandemic preparedness and the role of human challenge to accelerate vaccine development during outbreak, with industry speakers emphasising the great utility of human challenge in vaccine development. Public consent, engagement, and participation in human challenge studies were addressed, along with the role of embedded social science and empirical studies to uncover social, ethical, and regulatory issues around human infection challenge studies. Study volunteers shared their experiences and motivations for participating in studies. This report summarises completed and ongoing human challenge studies across a variety of pathogens and demographics, and addresses other key issues discussed at the meeting.